BACKGROUND: After acute myocardial infarction (AMI), treatment with beta-blockers and angiotensin-converting enzyme inhibitors (ACEI) is widely recognized as crucial to reduce risk of a subsequent AMI. However, many patients fail to consistently remain on these treatments over time, and long-term adherence has not been well described. OBJECTIVE: To examine the duration of treatment with beta-blockers and ACEI within the 24 months after an AMI. DESIGN: A retrospective, observational study using medical and pharmacy claims from a large health plan operating in the Northeastern United States. SUBJECTS: Enrollees with an inpatient claim for AMI who initiated beta-blocker (N = 499) or ACEI (N = 526) therapy. MEASUREMENT: Time from initiation to discontinuation was measured with pharmacy refill records. Associations between therapy discontinuation and potential predictors were estimated using a Cox proportional hazards model. RESULTS: ACEI discontinuation rates were high: 7% stopped within 1 month, 22% at 6 months, 32% at 1 year and 50% at 2 years. Overall discontinuation rates for beta-blockers were similar, but predictors of discontinuation differed for the two treatment types. For beta-blockers, the risk of discontinuation was highest among males and those from low-income neighborhoods; patients with comorbid hypertension and peripheral vascular disease were less likely to discontinue therapy. These factors were not associated with ACEI discontinuation. CONCLUSION: Many patients initiating evidence-based secondary prevention therapies after an AMI fail to consistently remain on these treatments. Adherence is a priority area for development of better-quality measures and quality-improvement interventions. Barriers to beta-blocker adherence for low-income populations need particular attention.
BACKGROUND: After acute myocardial infarction (AMI), treatment with beta-blockers and angiotensin-converting enzyme inhibitors (ACEI) is widely recognized as crucial to reduce risk of a subsequent AMI. However, many patients fail to consistently remain on these treatments over time, and long-term adherence has not been well described. OBJECTIVE: To examine the duration of treatment with beta-blockers and ACEI within the 24 months after an AMI. DESIGN: A retrospective, observational study using medical and pharmacy claims from a large health plan operating in the Northeastern United States. SUBJECTS: Enrollees with an inpatient claim for AMI who initiated beta-blocker (N = 499) or ACEI (N = 526) therapy. MEASUREMENT: Time from initiation to discontinuation was measured with pharmacy refill records. Associations between therapy discontinuation and potential predictors were estimated using a Cox proportional hazards model. RESULTS: ACEI discontinuation rates were high: 7% stopped within 1 month, 22% at 6 months, 32% at 1 year and 50% at 2 years. Overall discontinuation rates for beta-blockers were similar, but predictors of discontinuation differed for the two treatment types. For beta-blockers, the risk of discontinuation was highest among males and those from low-income neighborhoods; patients with comorbid hypertension and peripheral vascular disease were less likely to discontinue therapy. These factors were not associated with ACEI discontinuation. CONCLUSION: Many patients initiating evidence-based secondary prevention therapies after an AMI fail to consistently remain on these treatments. Adherence is a priority area for development of better-quality measures and quality-improvement interventions. Barriers to beta-blocker adherence for low-income populations need particular attention.
Authors: Dale R Burwen; Deron H Galusha; Jennifer M Lewis; Marjorie R Bedinger; Martha J Radford; Harlan M Krumholz; JoAnne Micale Foody Journal: Arch Intern Med Date: 2003-06-23
Authors: Kim A Eagle; Eva Kline-Rogers; Shaun G Goodman; Enrique P Gurfinkel; Alvaro Avezum; Marcus D Flather; Christopher B Granger; Steve Erickson; Kami White; Philippe Gabriel Steg Journal: Am J Med Date: 2004-07-15 Impact factor: 4.965
Authors: Yuka Kiyota; Sebastian Schneeweiss; Robert J Glynn; Carolyn C Cannuscio; Jerry Avorn; Daniel H Solomon Journal: Am Heart J Date: 2004-07 Impact factor: 4.749
Authors: Seth S Martin; Laurence S Sperling; Michael J Blaha; Peter W F Wilson; Ty J Gluckman; Roger S Blumenthal; Neil J Stone Journal: J Am Coll Cardiol Date: 2015-04-07 Impact factor: 24.094
Authors: Marguerite R Irvin; Daichi Shimbo; Devin M Mann; Kristi Reynolds; Marie Krousel-Wood; Nita A Limdi; Daniel T Lackland; David A Calhoun; Suzanne Oparil; Paul Muntner Journal: J Clin Hypertens (Greenwich) Date: 2012-08-03 Impact factor: 3.738
Authors: Diann E Gaalema; Rebecca J Elliott; Zachary H Morford; Stephen T Higgins; Philip A Ades Journal: Prog Cardiovasc Dis Date: 2017-01-05 Impact factor: 8.194
Authors: Jia-Rong Wu; Terry A Lennie; Marla J De Jong; Susan K Frazier; Seongkum Heo; Misook L Chung; Debra K Moser Journal: J Card Fail Date: 2009-12-11 Impact factor: 5.712
Authors: Robert B Schonberger; Carrie L Lukens; O Dicle Turkoglu; Jessica L Feinleib; Kenneth L Haspel; Matthew M Burg Journal: J Cardiothorac Vasc Anesth Date: 2012-03-13 Impact factor: 2.628
Authors: Ilene H Zuckerman; Xianghua Yin; Gail B Rattinger; Stephen S Gottlieb; Linda Simoni-Wastila; Sarah A Pierce; Ting-Ying Huang; Rahul Shenolikar; Bruce Stuart Journal: J Am Geriatr Soc Date: 2012-09-24 Impact factor: 5.562